Lipid-based nanocarriers for breast cancer treatment–comprehensive review

SV Talluri, G Kuppusamy, VVSR Karri, S Tummala… - Drug …, 2016 - Taylor & Francis
SV Talluri, G Kuppusamy, VVSR Karri, S Tummala, SRV Madhunapantula
Drug delivery, 2016Taylor & Francis
Breast cancer is the second leading cancer-related disease as the most common non-
cutaneous malignancy among women. Curative options for breast cancer are limited,
therapeutically substantial and associated with toxicities. Emerging nanotechnologies
exhibited the possibility to treat or target breast cancer. Among the nanoparticles, various
lipid nanoparticles namely, liposomes, solid lipid nanoparticles, nanostructured lipid carriers
and lipid polymer hybrid nanoparticles have been developed over the years for the breast …
Abstract
Breast cancer is the second leading cancer-related disease as the most common non-cutaneous malignancy among women. Curative options for breast cancer are limited, therapeutically substantial and associated with toxicities. Emerging nanotechnologies exhibited the possibility to treat or target breast cancer. Among the nanoparticles, various lipid nanoparticles namely, liposomes, solid lipid nanoparticles, nanostructured lipid carriers and lipid polymer hybrid nanoparticles have been developed over the years for the breast cancer therapy and evidences are documented. Concepts are confined in lab scale, which needs to be transferred to large scale to develop active targeting nanomedicine for the clinical utility. So, the present review highlights the recently published studies in the development of lipid-based nanocarriers for breast cancer treatment.
Taylor & Francis Online
以上显示的是最相近的搜索结果。 查看全部搜索结果